SCHEMBL14376105

SCHEMBL14376105

CC(N)(C#N)Cc1ccc(F)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LOXL2 Q9Y4K0 1/20 0.40
▸ ESR1 P03372 2/20 0.40
▸ ESR2 Q92731 2/20 0.40
▸ SLC6A2 P23975 2/20 0.38
▸ HTR2A P28223 1/20 0.38
▸ SLC6A4 P31645 1/20 0.38
▸ HRH1 P35367 1/20 0.38
▸ HTR2B P41595 1/20 0.38
▸ CHRNA4 P43681 1/20 0.38
▸ SLC6A3 Q01959 1/20 0.38
▸ DPP4 P27487 1/20 0.38
▸ TAAR1 Q96RJ0 4/20 0.38
▸ IDO1 P14902 3/20 0.36
▸ AGXT P21549 2/20 0.36
▸ AOC3 Q16853 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ TRPA1 O75762 1/20 0.35
▸ MAOB P27338 2/20 0.35
▸ MAOA P21397 1/20 0.35
▸ HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18801247 0.82 ESR1 (0.41) ESR1ESR2SLC6A2HTR2ASLC6A4
SCHEMBL9773274 0.81 LOXL2 (0.45) LOXL2SLC6A2HTR2ASLC6A4HRH1
SCHEMBL3832287 0.80 SLC6A2 (0.59) ESR1ESR2SLC6A2HTR2ASLC6A4
SCHEMBL3160096 0.80 ESR1 (0.42) LOXL2ESR1ESR2DPP4TAAR1
SCHEMBL9583291 0.78 IDO1 (0.44) SLC6A4TAAR1IDO1AGXTAOC3
SCHEMBL25343157 0.77 LOXL2 (0.48) LOXL2ESR1SLC6A2HTR2ASLC6A4
SCHEMBL349725 0.77 SLC6A2 (0.61) LOXL2SLC6A2HTR2ASLC6A4HRH1
SCHEMBL11567690 0.77 ESR1 (0.40) LOXL2ESR1ESR2SLC6A2HTR2A
SCHEMBL14446924 0.76 KDM4E (0.39) LOXL2ESR1ESR2DPP4TAAR1
Hydrochloric Acid SCHEMBL2799159 0.75 SLC6A2 (0.59) LOXL2SLC6A2HTR2ASLC6A4HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10662185-B2 Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-05-26 — — US disclosed
US-10662185-B2 Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-05-26 — — US disclosed
US-20190248783-A9 AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-08-15 — — US disclosed
US-20190248783-A9 AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-08-15 — — US disclosed
US-20180319794-A1 AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-11-08 — — US disclosed
US-10052312-B2 Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-08-21 — — US disclosed
EP-3272749-A1 AMINO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE Bayer Pharma Aktiengesellschaft (DE) 2018-01-24 — — EP disclosed
US-20170182014-A1 AMINO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-06-29 — — US disclosed
US-20170182014-A1 AMINO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-06-29 — — US disclosed
US-20170182014-A1 AMINO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-06-29 — — US disclosed
US-9624214-B2 Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-04-18 — — US disclosed
US-20150274719-A1 AMINO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-10-01 — — US disclosed
US-20150274719-A1 AMINO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-10-01 — — US disclosed
US-20150274719-A1 AMINO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-10-01 — — US disclosed
EP-2914594-A1 AMINO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE Bayer Pharma Aktiengesellschaft (DE) 2015-09-09 — — EP disclosed
US-20140179672-A1 Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-06-26 — — US disclosed
WO-2014068099-A1 AMINO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-05-08 — — WO disclosed
US-7312209-B2 Acridone inhibitors of IMPDH enzyme BRISTOL-MYERS SQUIBB COMPANY (US) 2007-12-25 — — US disclosed
CN-1113873-C Novel optionally substituted phenylimidazolidines, intermediates and process for prepn. thereof, use as drugs and pharmaceutical compositions contg. same ROUSSEL UCLAF CORP (FR) 2003-07-09 — — CN disclosed
CN-1141631-A Novel optionally substituted phenylimidazolidines, intermediates and process for prepn. thereof, use as drugs and pharmaceutical compositions contg. same ROUSSEL UCLAF CORP (FR) 1997-01-29 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179672-A1 Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use AADAC, TNNI3, PAICS LOXL2 3452/4885ESR1 3145/4885ESR2 2315/4885
US-10052312-B2 Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use AADAC, TNNI3, PAICS LOXL2 3452/4885ESR1 3145/4885ESR2 2315/4885
US-20190248783-A9 AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE AADAC, TNNI3, PAICS LOXL2 3452/4885ESR1 3145/4885ESR2 2315/4885
US-10662185-B2 Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use AADAC, TNNI3, TNNT2 LOXL2 3392/4885ESR1 3172/4885ESR2 2238/4885
US-20150274719-A1 AMINO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE AADAC, TNNI3, PAICS LOXL2 3452/4885ESR1 3145/4885ESR2 2315/4885
US-20180319794-A1 AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE AADAC, TNNI3, PAICS LOXL2 3452/4885ESR1 3145/4885ESR2 2315/4885
US-20170182014-A1 AMINO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE AADAC, TNNI3, PAICS LOXL2 3452/4885ESR1 3145/4885ESR2 2315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback